What is Late Breaking Clinical Research?
Late Breaking Clinical Research are always-popular sessions where speakers present the results of new or breaking research in heart failure. Featured on a plenary session stage, the Spotlight on Late Breaking Clinical Research sessions provide exposure and recognition for major randomized trials and registries that will likely have a significant impact on clinical practice or result in significant advances in the field. Additional rapid fire sessions will spotlight other clinical research in shorter oral presentations.
2025 Line-Up
Sunday, September 28 Plenary Session | 9:00 AM – 10:30 AM
Late Breaking Clinical Research 1: Devices and Cardiomyopathies
Integra-D Trial
- Effects of a Novel Cardiac Contractility Modulation-Defibrillator (CCM-D) on NYHA Functional Class in ICD-Indicated Patients: Post-Implant Results from the Integra-D Trial
FUTURE-HF
- Development of an Individualized Congestion Score using a Novel Implantable Inferior Vena Cava Sensor: the FUTURE-HF Trial Portfolio
DETECT-HF
- Development and Training of a Voice-Based Algorithm for Heart Failure Monitoring: Performance results from 599 Patients over 360,000 Patient-Days
FOREST-HCM
- Safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy: a 96-week analysis from FOREST-HCM
MAPLE-HCM
- Divergent Effect of Aficamten Versus Metoprolol on Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM
ATTRibute-CM
- Acoramidis Reduces Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM
HELIOS-B
- Reduction in Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B
Monday, September 29 Plenary Session | 9:00 AM – 10:30 AM
Late Breaking Clinical Research 2: Novel Therapies
VICTOR Trial
- Vericiguat efficacy and safety across baseline background therapy in contemporary ambulatory patients with HFrEF enrolled in the VICTOR trial
- Tolerability and safety of vericiguat in chronic heart failure with reduced ejection fraction
SEISMiC C
- Safety and Efficacy of Intravenous administration of Istaroxime for 48 hours in Patients with SCAI C Cardiogenic Shock due to acute heart failure
SUMMIT Trial
- Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis from the SUMMIT Trial
GARDEN TIMI-74
- GDF-15 Neutralization in Patients with Heart Failure: Primary Results of the GARDEN-TIMI 74 Trial
Danicamtiv Trial
- Danicamtiv Restores Ventricular and Atrial Function in Patients with Dilated Cardiomyopathy Caused by Genetic Variants that Depress Sarcomere Function
Sunday September 28 | Rapid Fire 1 | 10:45 AM - 11:45 AM
- Phase 1 Study of Daratumumab-Hyaluronidase for Reduction of Circulating Antibodies in Patients with High Allosensitization Awaiting Heart Transplantation
- Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Post-Heart Transplant Patients: A Multi-Center Retrospective Cohort Study
- Long Term Outcomes after LVAD Weaning for Myocardial Recovery: Results from the VAD Wean Recovery Network
- First-In-Human Implantation of a Next-Generation Membrane-Based LVAD
- Long Term Trajectory of Glomerular Filtration Rate Post-LAVD and the Impact on Clinical Outcomes: An analysis of the MOMEMTUM 3 Study
- Increased LVEF at Six Months Following LVAD Implant is Associated with Improved Long-Term Outcomes - A MOMENTUM-3 Analysis
- Screening for advanced heart failure in stable outpatients (The SAINTS study)
Sunday September 28 | Rapid Fire 2 | 2:15 PM - 3:15 PM
- Clinical Outcomes for Heart Failure at High Risk of Hyperkalemia according to Optimization of Agents Targeting the Renin-Angiotensin-Aldosterone System
- Intravenous Ferric Carboxymaltose in Patients With Ischemic Versus Non-Ischemic Etiology of Heart Failure and Iron Deficiency
- Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with SGLT2i and ARNI Instead of ACEI/ARB
- High-Dose IV Loop Diuretic Therapy and Ototoxicity Risk in Patients with Acute Heart Failure: Insights from the FASTR Trial
- Expanded Results from a Guideline-Directed Medical Therapy Clinic
- Optimized Heart Failure Therapy in Patients at Risk of Cardiac Wasting in Patients with Advanced Cancer: Results from the EMPATICC trial
- Supervised Exercise Training Improves Outcomes in Heart Failure: Evidence from the PACT-HF 2×2 Factorial Trial
Sunday, September 28 | Rapid Fire 3 | 4:15 PM - 5:15 PM
- Cardiac Contractility Modulation Reduces Mortality and Heart Failure Hospitalizations: A Matched Comparison of Patients Receiving and Not Receiving CCM Derived from a Real-World Dataset
- PROACTIVE-HF: 2-year outcomes, stratified by LVEF
- Outcomes of Poor Clinical Responders After Transcatheter Aortic Valve Replacement in Older Patients
- Invasive Hemodynamic Risk Stratification and Transcatheter Edge-to-Edge Tricuspid Repair: One-Year Results from TRILUMINATE Pivotal Trial
- Relationship between changes in seated pulmonary artery pressure, blood pressure, heart rate, and weight prior to heart failure hospitalization
- A Randomized Trial of a Remote, Digital Intervention Targeting Heart Failure Medical Therapy
- Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-invasive Multisensor Device
- Deep learning assisted prediction for occurrence of pacing-induced cardiomyopathy in the atrio-ventricular block
Monday, September 29 | Rapid Fire 4 | 12:00 PM – 1:00 PM
- Effect of vericiguat, compared with placebo, across baseline risk categories in chronic heart failure with reduced ejection fraction in the VICTOR Trial
- Effect of Vericiguat on Heart Failure Hospitalisation Events in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis
- Effect of Vericiguat on Mortality in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis
- Regional Variation in Outcomes and Response to Vericiguat in Heart Failure with Reduced Ejection Fraction: The VICTOR Trial
- Effect of the Soluble Guanylate Cyclase Stimulator Vericiguat on Health Status in the Phase 3 VICTOR Trial
- The Effect of Vericiguat on Mode of Death in Patients with Heart Failure with Reduced Ejection Fraction in the VICTOR Trial
- Rapidity of benefit of simultaneous initiation of finerenone and empagliflozin in people with chronic kidney disease and type 2 diabetes: the CONFIDENCE trial
- Dapagliflozin in Patients with Heart Failure: A Meta-Analysis of DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68
Submitting A Late Breaking Abstract
If an accepted late breaking clinical research abstract was submitted and accepted for abstract/poster presentation at the HFSA Annual Scientific Meeting, it needs to be withdrawn by August 15. Please notify Anna Leong at aleong@hfsa.org to ensure its status.
Submissions Portal Closed
Research accepted for presentation will be:
- Select clinical trials presented during the Late Breaking Clinical Research plenary session
- Timely clinical research will be spotlighted for short oral presentations during HFSA Spotlight/ Rapid Fire Abstracts session
- JCF encourages all accepted Late Breaking Clinical Research submitters to submit full papers for further consideration
- All late breaking data is embargoed subject to the HFSA policy below
Late breaking clinical research abstracts accepted for plenary sessions and Rapid Fire Oral Abstract sessions are strictly embargoed for release until the time of presentation at the Heart Failure Society of America’s Annual Scientific Meeting. Press releases may not be issued publicly in advance of the embargo.
Press Access Window (New for ASM 2025)
To facilitate accurate and timely reporting, HFSA will provide credentialed and registered media with embargoed access to late-breaking science materials beginning 24 hours before the embargo lifts.
- During this 24-hour window, journalists may access embargoed press releases, abstracts, and presenter information through a secure, password-protected folder managed by HFSA.
- Pre-embargo interviews with late-breaking science presenters may be scheduled during this time.
- Presenters may share approved embargoed institutional press releases with registered media during this period, provided the embargo date and time are clearly stated.* Please send your releases to marketing@hfsa.org to have your press release reviewed and included in the password-protected press access folder.
- Presenters may arrange interviews directly with registered media during the press access window, provided the embargo date and time are clearly stated and HFSA is notified.*
- All materials and interviews remain strictly embargoed until the official presentation time.
*HFSA does not share the full list of registered journalists, as this information is considered confidential and helps us maintain strong relationships with the press. However, we will share which major outlets are credentialed for ASM 2025 (e.g., The New York Times, MedPage Today, Cardiology Today, etc.) and can help facilitate connections with reporters when appropriate. Presenters are also welcome to work with their institution’s press office to distribute HFSA-approved embargoed releases and arrange pre-embargo interviews directly with journalists, provided the embargo is respected.
Media Outreach by Presenters
- Presenters may arrange interviews directly with registered journalists during the 24-hour press access window, provided embargo rules are respected.
- HFSA will not share the full list of registered journalists. However, HFSA may share which major outlets are credentialed (e.g., The New York Times, MedPage Today, Cardiology Today) and can facilitate introductions to reporters when appropriate.
- Institutional press offices may distribute HFSA-approved embargoed releases during the 24-hour window, but not before. Please send your releases to marketing@hfsa.org to have your press release reviewed and included in the password-protected press access folder.
Permissible Pre-Embargo Announcements
Prior to the embargo lifting, only the following information may be announced publicly:
- That the trial is completed.
- That results will be presented on [date/time] at HFSA ASM.
- What the trial assessed (basic design, questions, study population, interventions, etc.).
No results or any indirect reference to results may be included in announcements prior to the time of presentation.
After the Embargo Lifts
At the time of abstract presentation and anytime thereafter, researchers, authors, universities, medical institutions and health care organizations involved in the study may issue press releases and announcements to the public and media.
Sharing Your News with ASM Registered Media
To ensure that your Late Breaking Clinical Research release is brought to the attention of registered media and included in communications to registered press, please send your news release for a Late Breaking Clinical Research abstract being presented at ASM to marketing@hfsa.org. In the body of the email, please include the following:
- The full name of the abstract;
- The first and last authors’ names as they are listed on the abstract;
- The first and last name(s) of the main press contact(s) for this trial/research;
- The first and last name(s) and role(s) of individuals who will speak to press on behalf of the trial/research;
- Headshots of lead investigators and/or any supporting illustrations, graphics, tables, etc.; and
- If it is being published in a scientific journal, please include the name of the journal where it is being published or the name of the meeting where it will be presented, and the date/time of the anticipated publication.
Clinical research accepted for presentation will be:
- Either presented during the Late Breaking Clinical Research session
- Or presented during a Rapid Fire Spotlight Oral session
Notifications for Late Breaking Clinical Research will be sent by early August. Information on sessions and how to upload slides will be posted here and sent by mid-August.
If an accepted late breaking clinical trial abstract was submitted and accepted for general abstract/poster presentation at the HFSA Annual Scientific Meeting, it needs to be withdrawn by August 15, 2025.